The immunotherapy drugs market currently faces several challenges. High development costs of these drugs coupled with low success rates pose significant investment risks for pharmaceutical companies. Additional testing is needed to understand long term safety and efficacy profiles of these novel drugs. Many cancer types have remained untouched where immunotherapy shows little promise. Monotherapy response rates have been moderate so far and combination strategies need more data. Patient access has also been an issue due to high costs of these therapies.
Market Opportunities – Development of innovative immunotherapies
The drugs have shown promising results against several cancer types and their adoption is increasing. As more clinical evidence from combination regimens emerge, response rates are expected to improve. Newer immunotherapies continue to be tested against different cancer indications providing scope for label expansions. The approaches can also potentially be adapted for non-oncology diseases thereby, creating lucrative market growth opportunities over the forecasted period.
Immunotherapy Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients